A double-blind, placebo-controlled study of the effect of a TNFα antibody, certolizumab pergol (Cimzia), on microglial activation in amyloid PET positive patients with mild cognitive impairment due to AD-Intermediate likelihood (INMiND-01)

Trial Profile

A double-blind, placebo-controlled study of the effect of a TNFα antibody, certolizumab pergol (Cimzia), on microglial activation in amyloid PET positive patients with mild cognitive impairment due to AD-Intermediate likelihood (INMiND-01)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Therapeutic Use
  • Acronyms INMiND
  • Most Recent Events

    • 24 Mar 2016 Status changed from recruiting to discontinued as reported by ISRCTN: Current Controlled Trials.
    • 10 Jul 2015 Planned number of patients changed from 48 to 46 as reported by United Kingdom Clinical Research Network.
    • 14 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top